Status: Recruiting
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Participants needed: 148
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Cerium Pharmaceuticals, Inc.Updated: Jun 25, 2026Locations: 31
Eligibility criteria
Biopsy-proven membranous glomerulonephritis or a diagnosis of MN in patients wit... [+7]
Secondary membranous nephropathy as defined by history, physical exam, kidney bi... [+6]